logo
  

Transmode Shareholders Accept Infinera Buyout Offer

Infinera (INFN), provider of Intelligent Transport Networks, announced that its offer to acquire Transmode has been accepted by shareholders representing approximately 95.8 percent of the outstanding shares and votes in Transmode.

The transaction is now slated to close on or around August 20, 2015. Of the shares tendered, approximately 63 percent were tendered under the cash and stock mix alternative, and approximately 37 percent were tendered under the all-cash alternative. This will result in final consideration comprised of approximately 7.9 million shares of Infinera common stock and the remainder in cash.

In April, Infinera had announced its offer to acquire Transmode, a leader in metro packet-optical networking through a recommended public offer to the shareholders of Transmode.

As per the terms of the Offer, for every 10 shares of Transmode, shareholders would receive 300 Swedish kronor in cash and 4.705 Infinera shares. The purchase price implied a price per share of approximately 109 kronor, and a total equity value for Transmode of about $350 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT